Minghui Pharmaceutical announces strategic partnership and licensing agreement with Qilu Pharmaceutical to develop B7-H3 ADC in greater china

CAR-T Digest - August 2020

Weekly Digest - May 2025

09 May 2025: Minghui Pharmaceutical announces strategic partnership and licensing agreement with Qilu Pharmaceutical to develop B7-H3 ADC in greater china

Minghui Pharmaceutical has entered an exclusive licensing and collaboration agreement with Qilu Pharmaceutical for the development, manufacturing, and commercialization of its B7-H3-targeted ADC, MHB088C, in greater china
Under the agreement, Qilu gains exclusive regional rights to MHB088C, with Minghui eligible for payments totaling up to 1.345 billion RMB, including upfront, milestone, and royalty payments
MHB088C, developed using a proprietary SuperTopoi ADC platform, has shown potent anti-tumor activity and a strong safety profile in Phase 1/2 trials involving over 300 patients with advanced solid tumors
Data from subgroup analyses in small cell lung cancer and metastatic castration-resistant prostate cancer will be presented at the ASCO 2025 Annual Meeting, supporting the therapy’s potential across multiple indications
A Phase 3 trial for MHB088C in relapsed small cell lung cancer has been launched in China, further advancing its clinical development in the region